License Agreements - Additional Information (Detail)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2014
USD ($)
Sep. 30, 2012
EUR (€)
Jun. 30, 2011
USD ($)
May 31, 2010
USD ($)
Oct. 31, 2008
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Mar. 31, 2014
USD ($)
Mar. 31, 2012
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Acquired in process research and development costs           $ 500 $ 12,000     $ 800 $ 12,000  
Development cost receivable           1,258       1,258   $ 3,241
Research and development           54,338 76,138     196,675 193,256  
License Agreements Lucitanib                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Upfront payment | €   € 45,000,000                    
Sublicense agreement consideration               $ 13,600        
Additional payments receivable on milestone achievements | €   90,000,000                    
Additional payments receivable on attaining the sales target | €   250,000,000                    
Initial global development costs reimbursable | €   € 80,000,000                    
Development cost receivable           1,300       1,300   $ 3,200
Research and development           1,300 3,800     7,400 11,700  
Reduction in research and development expense for reimbursable development costs due from Servier           $ 1,300 3,800     7,700 $ 10,400  
License Agreements Licensor Pfizer | Rucaparib                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Acquired in process research and development costs $ 400                 500    
License Agreements Licensor Celgene Avilomics Research Inc | Name of drug product in licensed by the entity Rociletinib                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Sales milestone payments                   120,000    
License Agreement Terms | License Agreements Licensor Pfizer | Rucaparib                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Upfront payment     $ 7,000                  
Future expected development, regulatory and sales milestone payments                   264,500    
License Agreement Terms | License Agreements Licensor Pfizer | Rucaparib | First approval of NDA by FDA                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Future expected development, regulatory and sales milestone payments                   21,250    
License Agreement Terms | Advenchen Laboratories LLC | License Agreements Lucitanib                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Acquired in process research and development costs               3,400        
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements         25.00%              
License Agreement Terms | License Agreements Licensor Celgene Avilomics Research Inc | Name of drug product in licensed by the entity Rociletinib                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Upfront payment       $ 2,000                
Future expected regulatory and development payment                   $ 98,000    
License Agreement Terms | License Agreements Licensor Celgene Avilomics Research Inc | Name of drug product in licensed by the entity Rociletinib | Regulatory Milestone Payment                        
Research And Development Arrangement Contract To Perform For Others [Line Items]                        
Acquired in process research and development costs             $ 12,000 $ 5,000 $ 4,000